STOCKS TELEGRAPH

Tag: SLDB Stock

  • Biotech Boom: Solid Biosciences (SLDB) Stock Skyrockets On Positive Developments

    Biotech Boom: Solid Biosciences (SLDB) Stock Skyrockets On Positive Developments

    With a significant climb today, shares of Solid Biosciences Inc. (NASDAQ: SLDB) were up 48.39% on the charts at $5.98 as of the most recent check. The spike in SLDB stock follows two significant announcements.

    Motivating The INSPIRE DUCHENNE Trial’s findings

    SLDB’s Phase 1/2 INSPIRE DUCHENNE clinical study, which evaluated SGT-003, an advanced gene therapy option for Duchenne muscular dystrophy, showed encouraging preliminary results. Western blot examination of the first three study participants’ interim 90-day biopsy results showed an average microdystrophin expression of 110%. Furthermore, multiple biomarkers indicated improved muscle health and resilience.

    The study employed three distinct measurement techniques, all supporting the high expression levels of the microdystrophin transgene. Significantly, improvements in muscle integrity were indicated by decreases in important clinical indicators linked to muscle degeneration. Solid Biosciences plans to discuss a simplified approval process for the therapy with the U.S. Food and Drug Administration (FDA) by mid-2025.

    Favorable Safety Profile in Initial Participants

    SGT-003 demonstrated a favorable safety profile among the first six participants dosed by the data cutoff date of February 11, 2025. After more than 20 days of treatment, all individuals had experienced adverse events (AEs) that were characteristic of AAV gene therapy. There were no significant adverse events (SAEs) or unexpected severe reactions were reported.

    Offering of Stock to Raise $200 Million

    Concurrently, Solid Biosciences said that 35,739,810 shares of common stock will be priced at $4.03 per share in an underwritten public offering. Furthermore, 13,888,340 shares of pre-funded warrants were issued at a price of $4.029 each. The offering is scheduled to close on or around February 19, 2025, and the business expects to raise around $200 million in gross proceeds.

    The exercise price for each pre-funded warrant is $0.001 per share, and it can be exercised until it is used up completely. Solid Biosciences is selling all of the equities in this offering, strengthening the company’s financial standing as it pursues its cutting-edge gene therapy projects.

  • FDA Nod Sends Solid Biosciences (SLDB) Soaring In Extended Session

    FDA Nod Sends Solid Biosciences (SLDB) Soaring In Extended Session

    Following a crucial regulatory milestone, Solid Biosciences Inc. (NASDAQ: SLDB) saw a notable increase in the value of its shares. Tuesday’s after-hours trade saw SLDB shares increase 17.35% to $4.60. The spike was propelled by the FDA’s approval of Investigational New Drug or IND application for SGT-212, the company’s new gene therapy candidate that targets Friedreich’s ataxia (FA).

    Novel Gene Therapy

    Friedreich’s ataxia is a degenerative, multisystem illness brought on by low levels of the frataxin protein. Solid Biosciences’ SGT-212 is a novel treatment for this condition. The treatment uses an AAV-based delivery method that may be administered directly into the cerebellum via intradentate nuclei (IDN) or systemically by intravenous (IV) infusion. This dual-targeting strategy aims to address both the neurological and systemic manifestations of FA, offering a comprehensive solution for disease progression.

    Friedreich’s ataxia presents unique challenges for drug development due to the need for precise frataxin expression levels to prevent cardiac toxicity and targeted delivery to cerebellar tissues for neurological benefits. SGT-212 stands out as the only candidate addressing both cardiac and neurological complications by leveraging its dual-route delivery system.

    Preclinical Success and a Differentiated Approach

    Solid Biosciences’ preclinical studies have demonstrated the potential of SGT-212 to safely deliver frataxin to critical tissues. The results showed significant improvements in neurological function and reversal of cardiac symptoms in animal models. SLDB’s extensive research, including long-term non-human primate studies, supports its belief that targeting multiple systems via dual administration is the most effective strategy for addressing FA’s diverse impacts.

    Clinical Trials on the Horizon

    Solid Biosciences is in further plans to launch a first-in-human Phase 1b clinical trial of SGT-212 in the latter half of 2025. This open-label, dose-finding study will include both ambulatory and non-ambulatory adult patients with FA across up to three cohorts. The trial will evaluate the safety and tolerability of the dual-administration approach, with participants being monitored for up to five years post-treatment.

    Solid Biosciences (SLDB) also announced a conference call scheduled for today before the market opens, aiming to provide further details on this milestone and its broader pipeline developments.

  • What Ignited The Market For Solid Biosciences (SLDB) Stock?

    What Ignited The Market For Solid Biosciences (SLDB) Stock?

    As the US stock market continues to play out, Solid Biosciences Inc. (NASDAQ: SLDB) has seen a remarkable increase in the value of its shares during current activity. According to the most recent check, Solid Biosciences stock has risen by a significant 29.41%, closing at $7.70. This surge is underpinned by a strategic maneuver on the part of Solid Biosciences, marked by a consequential disclosure pertaining to equity.

    Solid Biosciences (SLDB) has made a distinct mark by entering into a securities purchase agreement with a discerningly selected cohort of institutional accredited investors. This agreement encapsulates a substantial private placement, amounting to approximately $108.9 million.

    This private placement is expected to close on January 11, 2024, or thereabouts, assuming the usual closing conditions are met. Notably, this private placement has been priced precisely to satisfy the strict “Minimum Price” criterion while also carefully adhering to Nasdaq standards.

    Participation in the private placement spans both novel and existing investors, comprising an illustrious consortium including Adage Capital Partners LP, Invus, Janus Henderson Investors, Bain Capital Life Sciences, Perceptive Advisors, Deerfield Management Company, RA Capital Management, Vestal Point Capital, LP, and an undisclosed life sciences investor, among other stakeholders.

    In the orchestration of this private placement, Citigroup and Cantor have assumed the roles of joint lead placement agents for SLDB. The private placement itself encompasses the sale of 16,973,103 shares of common stock by Solid Biosciences at an individual share price of $5.53. Concurrently, pre-funded warrants offering the right to acquire up to 2,712,478 shares of common stock are being proffered at a rate of $5.529 per pre-funded warrant, in lieu of common stock.

    Each pre-funded warrant is endowed with an exercise price of $0.001 per share, immediate exercisability, and maintains exercisability until complete execution. The generated net proceeds from this private placement are allocated to bolstering ongoing pipeline development initiatives, facilitating business development endeavors, and attending to working capital and overarching corporate exigencies for SLDB.

  • Solid Biosciences Inc. (SLDB) stock Yields to Corrections After Hours Following its Huge Gain

    On March 11, Solid Biosciences Inc. (SLDB) plunged under corrections in the after-hours following its huge gain in the regular session. There is no official announcement or SEC filing from the company to explain the recent gains.

    During the regular trading session, SLDB gained a huge 37.38% after fluctuating between $0.7210 and $1.1300. The stock closed the session at a price of $1.0600 per share while 7.04 million shares exchanged hands. Consequently, the stock succumbed to corrections in the after-hours to lose 8.49%. Hence, SLDB was trading at a value of $0.9700 in the after-hours on Friday.

    The Duchenne muscular dystrophy (DMD) treatment’s developer, Solid Biosciences Inc. was founded in 2013. Currently, its 110.3 million outstanding shares trade at a market capitalization of $116.91 million.

    SLDB Stock Movements

    Expanding sanctions and cyberattacks of Russia struck a blow to most of the stocks on March 8. While the classics saw an upsurge including basic material, others witnessed a downfall. The healthcare sector suffered immensely, as a huge number of stocks reached new lows. Among these, SLDB also reported its new low on March 08. Following this, the stock entered a mild uptrend that continued till March 10. On March 11, the stock’s bullish momentum escalated as it increased by a huge 37.38%. Moreover, the 5-day gains of the stock totaled 40.71%, which ultimately called for corrections in the after-hours.

    With no recent news from the company, it seems the stock’s movements are due to external factors including the contribution from the recent low.

    Recent Participations

    Source: BioSpace

    Recently, the company participated in the SVB Leerink 11th Annual Global Healthcare Conference. SLDB’s Chief Operating Officer Joel Schneider and Chief Scientific Officer Carl Morris participated in a fireside chat at the conference on Thursday, February 17, 2022.

    Before this, the company’s CEO, President, and Co-Founder IIan Ganot presented at the 40th Annual J.P. Morgan Healthcare Conference on January 13.

    SLDB’s Financials

    On November 03, the company reported its financial results for the third quarter of 2021.

    In Q3 2021, SLDB had collaboration revenue of $3.5 million while there was none in 2020.

    Moreover, the company incurred a net loss of $18.0 million in Q3 2021, against $21.2 million in the year-ago period.

    Furthermore, the company ended the quarter with cash, cash equivalents, and available-for-sale securities of $229.8 million on September 30, 2021.

  • Solid Biosciences (NASDAQ: SLDB) Is Soaring Today. Here’s Why

    Shares of Solid Biosciences Inc. (NASDAQ: SLDB) has traded up 70.44% after the company announced that the US Food and Drug Administration (FDA) gave the permission to resume the IGNITE DMD Phase I/II clinical trial of the company. On July 24, 2020, the company has revealed that it has received the written notice from FDA that its Phase I/II clinical trial of IGNITE DMD will be halted. FDA has requested the information and safety and efficacy data related to the trial.

    Solid Biosciences has provided all the necessary details about the IGNITE DMD Phase I/II clinical trial. The company’s data has fulfilled all the requirements of the FDA and satisfied the drug administration authority. The company has promised to share all the manufacturing details with the FDA and all the changes that remove the majority of empty viral capsids, allowing target dosing to be achieved with fewer viral particles.

    The step of the company to lessen the total amount of virus delivered to each patient is to aid safe dosing of SGT-001 for the duration of the IGNITE DMD trial. In July, the written notification which the company received from FDA has also requested the comparability between SGT-001 made using Solid’s prior manufacturing process and its current, improved process.

    Solid Biosciences has received the FDA acknowledgment by giving the full details of SGT-001 two manufacturing processes. FDA has earlier halted the IGNITE DMD trial after the adverse effects of dosing in the sixth patients in November 2019. Solid Biosciences then gave all the details to the FDA in April 2020.

    In May 2020, the company received the notice of hold on the IGNITE DMD clinical trial. And in July FDA has requested manufacturing information, updated safety, and efficacy data for all patients dosed, and providing direction on total viral load to be injected per patient.

    Solid Biosciences Inc. (NASDAQ: SLDB) shares were trading up70.44% at $3.46 on Thursday. Solid Biosciences Inc. share price went from a low point around $1.93 to briefly over $13.58 in the past 52 weeks, though shares have since pulled back to $3.46. It has moved up 79.27% from its 52-weeks low and moved down -74.52% from its 52-weeks high. SLDB market cap has remained high, hitting $152.66 million at the time of writing.

    SGT-001 of Solid Biosciences is a novel adeno-associated viral (AAV) vector-mediated gene transfer therapy manufactured to treat the underlying genetic cause of Duchenne. Duchenne is caused by mutations in the dystrophin gene that result in the absence or near absence of dystrophin protein.